Who can get a Covid booster this spring and what do private jabs cost?
Around 7.5 million people in England are eligible for a top-up vaccination.
Many pharmacies also sell the Covid jab privately.
Eligible members of the public in England can have a spring booster between 1 April to 17 June.
Vaccinations are being offered to:
adults aged 75 years and over
residents in a care home for older adults
people aged between six months and 74 years who have a weakened immune system and are at a greater risk from severe illness
Those who turn 75 years old between 1 April and 17 June 2025 can also have the jab.
NHS England says it is contacting everyone who qualifies by text, email, app message or letter.
However, those who qualify do not have to wait for an invitation and can visit the NHS website, use the NHS app or call 119 to book an appointment.
In different parts of the UK, the groups who qualify for a spring booster are the same but the dates of the campaign are slightly different:
Scotland: 31 March until 30 June
Wales: 1 April until 30 June
Northern Ireland: 7 April until 30 June
The NHS uses vaccines from two companies across the UK: Pfizer-BioNTech and Moderna.
People are advised to take whichever vaccine they are offered, as both provide protection against severe illness or death.
Data from the UK Health Security Agency - based on the 2024 spring vaccination programme - showed those who received a vaccine were more than 40% less likely to be admitted to hospital with Covid for up to two months after their jab, compared to those who did not receive one.
AstraZeneca pulled its Covid vaccine worldwide because of the surplus of updated vaccines from its competitors.
At the firm's request, in May 2024, the European Medicines Authority withdrew authorisation for the vaccine, which is no longer being manufactured or supplied.
A number of High Street chemists and private clinics sell and administer the Pfizer Covid vaccine directly to the public.
The cost per single dose varies but is typically between £75 and £99.
You need to be aged 12 or above, and must not have had a Covid vaccine in the previous three months. You also need to talk to a health professional to check that it is suitable.
A protein-based booster vaccine made by Novavax, which works differently to the Pfizer and Moderna jabs, is also available.
Moderna hopes to launch a combined flu and Covid vaccine later in 2025 or 2026, after the jab passed a vital part of final-stage scientific checks in June 2024.
Pfizer is also testing a similar two-in-one vaccine against flu and Covid.
If you have Covid, or think you might, the NHS recommends delaying vaccination until you feel better.
It also advises postponing if you have a high temperature or feel otherwise unwell with any illness.
However, there is no need to wait if you have recently recovered from Covid and feel well. The vaccines do not infect people with Covid, and cannot cause positive test results.
What to do if you have Covid
XEC Covid variant: What are the symptoms and is it spreading in the UK?
For most people, side effects are mild. The most common include a sore arm, headache, chills, fatigue and nausea.
They are part of the body's normal immune response to vaccination and tend to resolve themselves within a day or two.
Very rarely myocarditis - inflammation of the heart muscle - has been linked to the Moderna and Pfizer vaccines.
A very small number of people have experienced a severe allergic reaction after the Pfizer vaccine.
Patients with serious allergies should talk to their healthcare professional before being vaccinated.
Covid vaccine safety - What we know
Rise of vaccine distrust - why more of us are questioning jabs
Is the system letting down people who were harmed by Covid vaccines?
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Pfizer Inc. (PFE) Finalizes Global Licensing Agreement with 3sbio, Inc.
Pfizer Inc. (NYSE:PFE) is among the . On July 24, 2025, Pfizer Inc. (NYSE:PFE) finalized the global licensing agreement with 3SBio, Inc. With this agreement, PFE acquired the exclusive rights to develop, manufacture, and commercialize 3SBio's SSGJ-707, a bispecific antibody for PD-1 and VEGF. Leveraging 3SBio's proprietary CLF2 platform, this innovative treatment enhances Pfizer's oncology pipeline and solidifies its competitive edge in cancer research. The antibody is presently undergoing clinical trials in China for non-small cell lung cancer (NSCLC) with promising interim Phase 2 results. It is also under clinical trials for gynecological tumors. By manufacturing the drug in the U.S. and expanding clinical trials globally, Pfizer Inc. (NYSE:PFE) aims to focus on Phase 3 studies for NSCLC and other solid tumors. Pfizer Inc. (NYSE:PFE) will make an upfront payment of $1.25 billion to 3SBio and acquire a $100 million equity stake, as per the agreed terms. With up to $150 million in potential payments, Pfizer Inc. (NYSE:PFE) can exercise the option to extend the agreement for exclusive rights in China. Operating globally, Pfizer Inc. (NYSE:PFE) discovers, develops, and sells biopharmaceuticals. It is one of the best ESG stocks. While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 11 Best Mineral Stocks to Buy According to Hedge Funds. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
The six natural alternatives to statins to lower your cholesterol
For those of us in middle age and beyond, conversations about cholesterol are hard to avoid – and with good reason. In England, according to the National Institute for Health and Care Excellence, high cholesterol leads to more than 7 per cent of all deaths and affects six in 10 adults, a number that rises for those in middle age: the most recent NHS Health Survey for England found that in the 45-64 age group, 77 per cent of women and 67 per cent of men had raised cholesterol. Surprisingly, these figures drop in the over-64 age group. Why? Because many of this older cohort are on statins. Statins are currently prescribed to around eight million people in the UK, and taking this daily tablet is a proven way to lower cholesterol levels and reduce your risk of heart attack or stroke. 'We are the first generation of people who have the opportunity to reduce our cardiovascular risk – still the number-one killer – because we have effective treatments in the form of statins,' says Robin Choudhury, a professor of cardiovascular medicine at the University of Oxford, a consultant cardiologist at John Radcliffe Hospital and the author of The Beating Heart: The Art and Science of Our Most Vital Organ. The turn against statins However, for some people with a lower cardiovascular risk, it may be possible to avoid statins by adopting lifestyle changes and/or seeking out other natural options. This is welcome news for many, because statins are often viewed with mistrust. Some critics argue that perhaps these pills are being doled out too liberally and that lots of people shouldn't be on them at all. Others think that statins may even be bad for us. In his 2007 book The Great Cholesterol Con, Scottish GP Malcolm Kendrick argues that high cholesterol levels don't cause heart disease, that statins have many more side effects than has been admitted and that their advocates should be asking more questions. This is something Prof Choudhury finds mystifying. 'I really don't know why people are reluctant to take them,' he says. 'There is one serious side effect associated with statins, called rhabdomyolysis, which is a severe muscle inflammation. But it's extremely rare. It affects one to two patients per 10,000 treated.' 'A lot of people just don't want to take a tablet every day,' suggests Dr Oliver Guttmann, a consultant cardiologist at the Wellington Hospital, part of HCA Healthcare UK. 'People also want to try and do it in what they call the 'natural' way.' The other natural options So, are there other effective natural options to statins? The answer is yes – but only up to a point. 'The bottom line,' says Dr Guttmann, 'is that with all the natural alternatives, there's some effectiveness, but they're not magic bullets.' He accepts, however, that other natural options can play 'a supporting role, especially for those people who are generally healthy and just want to try complementary treatments to decrease mild cholesterol elevation'. If you have been offered statins and decide not to take them, it's crucial to discuss the risks with your GP or cardiologist. Prof Choudhury emphasises that if you've already had a heart attack, angina or stroke, or if your percentage risk of a future event is high, taking statins is usually a sensible route that is grounded in evidence. 'For those who have heart disease, very few people have a good reason not to be on statins. For those who've never had an event, it's important to take an holistic view of risk [incorporating blood pressure, diabetes and family history] but for many individuals, alternatives to statins are perfectly reasonable.' Here are six other cholesterol-lowering options to consider: Plant sterols and stanols Plant sterols and stanols, also known as phytosterols, are naturally occurring compounds that have a similar structure to cholesterol. Prof Choudhury explains: 'They help lower LDL cholesterol levels by reducing cholesterol absorption in the gut because they compete for the same absorption sites.' Found in foods such as vegetable oils, nuts, seeds and whole grains, phytosterols have been shown to lower LDL cholesterol by eight to 10 per cent when eaten regularly as part of a healthy diet. They also work well in combination with statins. However, according to the British Dietetic Association, you need to consume reasonably large quantities – around 2g – each day, with meals, for them to be effective. Most people achieve this by having a plant sterol- or stanol-fortified mini yogurt drink every day or by eating two to three portions of foods with at least 0.8g of added plant sterol/stanol, such as 10g of fortified spread (eg margarines) or one 250ml glass of fortified milk. Oats and barley Oats and barley contain beta-glucans, a soluble fibre, which can be consumed in food or as supplements to regulate blood sugar and lower cholesterol. Cholesterol can go into the blood or the gut, Prof Choudhury explains. 'If you can take that cholesterol out of the gut and stop it being reabsorbed, that has a beneficial net effect on blood cholesterol levels. Beta-glucans bind to the soluble cholesterol that's in the gut and it then exits the bowel.' Some studies suggest that if a healthy adult consumes around 3g of beta-glucan daily – a bowl of porridge – they can decrease their LDL levels by five to 10 per cent over three months. Omega-3s Omega-3 fatty acids do not lower LDL cholesterol, but they have been shown to reduce triglycerides – a different type of fat found in the blood that are deemed to be harmful. Taken in supplement form, omega-3 can lower triglycerides by around 20-30 per cent. 'I tell my patients to take omega-3s all the time,' says Dr Guttmann. 'You find them in oily fish, like salmon and mackerel, though most people take them in supplement form. They work really well taken together with statins to lower your risk of heart disease. They've also been shown to support your brain health, cognitive function and mood.' Red yeast rice Commonly used in traditional Chinese medicine, red yeast rice is sometimes described as a natural statin. 'It blocks cholesterol production in the liver in a similar way to statins,' Dr Guttmann explains. 'The problem is, it's very difficult to get the exact amount you need because the dosages and qualities can vary from one supplement to another. People can also sometimes consume red yeast rice in very high doses, which may cause liver problems.' Prof Choudhury is also concerned by the unregulated nature of red yeast rice capsules, which have been linked to safety issues. 'Statins originated from yeast,' he says, 'and there's a component of red yeast rice [a compound called monacolin K] which has a statin-like action that lowers LDL cholesterol. But it's not a regulated product, so you don't know what you're getting when you take it.' Psyllium husk Psyllium husk is a soluble fibre that helps to lower LDL cholesterol levels. When consumed, it forms a gel-like substance in the digestive tract that traps bile acids and prevents their absorption, causing them to be excreted through the stool. The liver responds by pulling in cholesterol from the blood to produce more bile acids, reducing the amount of cholesterol circulating in the blood. 'Psyllium husk is basically a digestive aid,' says Dr Guttmann. 'It's used as a laxative because it helps regulate your bowel movement, and in the process, it can lower cholesterol and decrease reabsorption. If you take it regularly, it probably reduces your LDL level by about five per cent. So it's great if you just want to be living a healthier lifestyle but inadequate as a medical intervention.' Garlic Some research suggests that allicin, a chemical found in garlic, can lower your blood pressure and cholesterol. One clove (3-6g) of garlic a day may help decrease your LDL by up to 10 per cent, though the evidence is not yet conclusive. 'The problem is that if you just eat fresh garlic, you need to consume a very high amount,' says Dr Guttmann. 'And that's difficult for most people to achieve. So most people take garlic supplements in quite a high dose. I advise people to try this for a while and then re-monitor their LDL to see how they react to it. But it's certainly not a replacement for statins.' And one to be sceptical about… Apple cider vinegar 'The one product often mentioned as an alternative to statins that doesn't really have any significant evidence to back it up is apple cider vinegar,' says Dr Guttmann. 'While it might help to decrease your sugar levels, it does not appear to affect your LDL significantly.' Prof Choudhury concurs: 'I'm not aware of any convincing evidence to suggest that this is effective.' Lifestyle changes to lower your cholesterol 'Our cholesterol level is, to a large extent, genetic,' says Prof Choudhury. 'With lifestyle modifications, you can make some impact on it, though usually not more than 10-15 per cent. For people who don't have very high cholesterol, but have other risk factors, it's a sensible thing to do.' There are five main ways to reduce your cholesterol level without taking statins: Eat a healthy, balanced diet that's high in fibre Exercise regularly Maintain a healthy weight Limit the amount of alcohol you drink Stop smoking For Dr Guttmann, increasing our consumption of dietary fibre is perhaps the quickest and easiest lifestyle change to make. 'Eating a high-fibre diet not only improves your gut health, it also decreases your cholesterol absorption. It binds to the cholesterol in your gut and prevents it being absorbed by the body, which lowers your levels of harmful LDL cholesterol.' He adds: 'My patients often ask me, 'If I do all of these things, surely it's the same as taking a statin?' But the truth is, because they're all working in a similar way, the benefits are not cumulative.' He does concede, however, that it very much depends on the individual. 'I've had some patients surprise me,' he nods. 'By changing their diet and lifestyle and by incorporating some of the interventions in the list above, people can achieve dramatic improvements. But, overall, statins are still the gold standard.' Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Forbes
6 hours ago
- Forbes
Israeli Startups Using AI To Accelerate Drug Discovery
AI Aiding in drug discovery Israel-based AION Labs wants to drive AI to revolutionize pharmaceutical drug discovery and development. AION is an innovative venture that brings together pharmaceutical heavyweights—Pfizer, AstraZeneca, Teva, and Merck—with entrepreneurial scientists, technology leaders, and successful investors. 'We are a venture studio that builds startups using computational technologies and artificial intelligence to unleash new capabilities to discover and develop new drugs with a venture model that we invented,' says Mati Gill, CEO of AION. This unique collaboration addresses a costly endeavor that is crucial to the quality of our lives. It takes $5 billion and ten years to bring a new drug to market. The world's top 20 pharmaceutical companies collectively spent $145 billion on R&D in 2022-23, according to a recent Deloitte report, which also noted 'AI is yet to become a 'game-changer' in pharma R&D.' A more comprehensive survey of 4,191 pharmaceutical companies worldwide, published in Nature Reviews Drug Discovery, found that they spent $276 billion on R&D in 2021. These R&D expenses have increased tenfold since the 1980s (after adjusting for inflation), and pharmaceutical companies now allocate approximately 25% of their revenue to R&D, nearly double the share seen in the early 2000s, according to CB Insights. 'AI could potentially cut years off the discovery process and compress clinical trial times by up to 30%. This would accelerate the delivery of new treatments to patients, unlock novel treatment approaches, and enable more personalized medicine,' noted CBI. Another CBI report, on the AI readiness of pharmaceutical companies, highlighted the importance of external collaboration, 'as breakthrough innovations increasingly emerge from partnerships rather than internal development alone.' Gill predicts that by 2030, the first truly AI-designed drugs will reach regulatory approval. He believes that Israel is uniquely positioned to be a leading ecosystem in transforming the global biotech and pharmaceutical landscape, given its strengths in multidisciplinary scientific discovery, entrepreneurial innovation, computational biology and big data analysis, as well as a robust and integrated healthcare system, and strong government support. 'For the first time, Israel's strengths are coinciding with what the future of the industry is going to be,' says Gill. There are three core principles behind every startup that AION selects and supports, explains Gill: they address a validated, well-defined, industry-wide problem statement; there's a multidisciplinary team that has expertise in both AI and biology and a technology that can solve that problem statement; and that at least one of AION' pharmaceutical partners is willing to commit to working with the startup to initially develop their technology and conduct with them a proof-of-concept at an early stage. The R&D teams of AION Labs' partners help select the specific industry-wide challenges to focus on and the technologies and scientist-led startups that will develop the solutions. To accomplish that, AION has established two tracks, one starting with the problem statement and the other starting with the technology. DenovAI is an example of starting with the problem statement. Is it possible to design proteins 'de novo' or completely from scratch? 'We ran a challenge and had 15 great candidates,' recounts Gill. 'We selected a senior scientist who had developed a technology called AlphaDesign that is basically doing the inverse of the famous AlphaFold.' The startup recently demonstrated its ability to generate new proteins with measurable, targeted function. Its AI-based platform for rapid de novo antibody discovery could reduce the discovery process from months to days, and broaden the scope of therapy to a wide range of diseases. Cassidy Bio is an example of starting with the technology. It is using large language models or LLMs to design new guide RNAs, unlocking the capability of gene therapy in a scalable and precise manner. Guide RNAs or gRNAs serve as the 'GPS' for CRISPR systems, directing the editing machinery to precise genetic targets. The design of gRNAs plays a critical role in determining both the efficacy and safety of gene-editing therapeutics. Professor Ayal Hendel of Israel's Bar-Ilan University, a leading expert in genome editing and gene therapy, teamed up with two experienced entrepreneurs to establish the startup. With AION Labs' help, they raised $8 million in seed funding and are working with AstraZeneca to validate their technology. Based on proprietary, clinically relevant genomic data generation, state-of-the-art predictive algorithms, and rigorous wet lab validation, Cassidy Bio is developing the first comprehensive predictive platform based on LLMs for gRNA design. Unlike the data driving AI consumer applications, which is mostly based on internet-scraped data, pharmaceutical data is proprietary data. AION Labs' unique collaborative model provides access to pharmaceutical firms' R&D teams and their data, along with a secure sharing environment facilitated by AION's tech partner, Amazon's cloud service. This means the pharmaceutical companies can share their proprietary data with the startups in AION Labs' portfolio, but not with each other. AION Labs is also a member of Israel's 8400 The Health Network. This network was founded in 2017 on the premise that HealthTech is Israel's next economic growth engine and that Israel has what it takes to become a game-changing player in the global HealthTech revolution, according to its CEO, Ari Strasberg. To date, the non-profit organization has developed numerous programs and national initiatives, ranging from HealthIL, which bridges the gap between healthcare systems and technology by facilitating over 1,300 pilots and implementing 160 projects, to Helix, which strengthens the working relationships between 46 top U.S. and Israeli HealthTech leaders. The organization has been very successful, says Strasberg, in creating a public-private partnership, connecting government programs with 'the needs of the ecosystem.' Another success story is the development of FIRE, the data interoperability standard used by the healthcare systems in Israel. Going forward, Strasberg would like 8400 to play a major role in increasing the number of very successful Israeli HealthTech startups. 'We have a few, but not enough,' says Strasberg. 'We need to have a few blockbuster ones that carry the entire ecosystem with them.'
